References

37. Eisert et al. In Michelson AD, 2nd ed. Chap 63. Platelets Amsterdam: Elsevier 2007: 1165–1179.
38. Eisert WG. in Platelets (Academic Press) 2002: 803-815.
39. Eisert WG. Neurology 2001, 57: S20-S23.
40. Eisert WG. Am J Ther 2001, 8: 443-449.
41. ESO Guidelines 2008. Publication pending.
42. The ESPRIT Study Group. Lancet 2006; 367: 1665-1673.
43. The ESPS 2 Study Group. J Neurol Sci 1997; 151 (Suppl): S1–S77.
44. Feigin et al. Lancet Neurology, 2003; 2: 43–53.
45. Fields WS, Lemak NA, Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia. Stroke 1977; 8: 301-316.
46. Feinberg WM, Albers GW, Barnett HJM, et al. Guidelines for the management of transient ischemic attacks. Stroke 1994; 25: 1320-1335.
47. Fitzgerald et al. J Clin Invest 1983, 71: 676-688.
48. Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. 63 Federal Register 56802 (1998) (codified at 21 CFR §343).
49. Food and Drug Administration revised January 31, 2007, NDA 20-84/S-012: Page 16.
50. Glasser et al. Am Heart J 1996; 131: 379–384.
51. Guiraud-Chaumeil B, Rascol A, David J, et al. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires. Rev Neurol (Paris) 1982; 138: 367-385
52. Hadi et al. Vascular Health and Risk Management 2005; 1(3): 183-198
53. Halkes et al 2008. Full publication pending.
54. Hanson SR, Harker LA, Bjornsson TD. Effects of platelet-modifying drugs on arterial thromboembolism in baboons: aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest 1985; 75: 1591-1599
55. Hankey. Cerebrovasc Dis 2003; 16 (Suppl 1): 14–19.
56. He et al. 1998. JAMA 1998; 280: 1930–1935.
57. Hirsh et al. Chest . 1995;108 (Suppl): 247S-257S.
58. Honour AJ, Hockaday TDR, Mann JI. The synergistic effect of aspirin and dipyridamole upon platelet thrombi in living blood vessels. Br J Exp Pathol 1977; 58: 268-272.
59. Hurwitz et al. JAMA 1997; 278 (8): 659-662.
60. Johnston et al. Lancet 2007; 369: 283-292.
61. Johnston et al. JAMA 2000; 284: 2901–2906.
62. Johnson ES, Lanes SF, Wentworth CE III, et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999; 159: 1248-1253.
63. Kallmann R, Nieuwenhuis HK, de Groot PG, et al. Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 excretion in healthy subjects. Thromb Res 1987; 45: 355-361.
64. Lauri D, Zanetti A, Dejana E, et al. Effects of dipyridamole and low-dose aspirin therapy on platelet adhesion to vascular subendothelium. Am J Cardiol 1986; 58: 1261-1264.
65. Lavallée et al. Lancet Neurol 2007; 6: 953-960.
66. Leonardi-Bee et al. Stroke 2005; 36 (1): 162-168.
67. Lindgren, A.; Husted, S.: Dipyridamole and headache - does dose titration help? In: Update on stroke therapy. Wahlgren, N.G.; Ahmed, N.; Hårdemark, H.-G. (Eds.). Karolinska Stroke Update, Stockholm, 2003.
68. Lipton et al. Neurology 2004; 63: 1099–1101.
69. Malinin A. HeartDrug 2002, 2: 93-104.
70. Masotti et al. Lancet . 1979;2:1213-1216.
71. Mohr. Neurology 2004; 62 (8Suppl6): S3–S6.
72. Moncada S, Korbut R. Lancet . 1978;1:1286-1289.
73. Moncada S, Vane JR. N Engl J Med 1979, 300: 1142-1147. Müller TH, Su CAPF, Weisenberger H, et al. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990; 30: 179-186.